MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer

[1]  Wei Gou,et al.  MiR‐552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression , 2018, Journal of cellular and molecular medicine.

[2]  Qi Zhao,et al.  miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1 , 2018, Hematology.

[3]  G. Lin,et al.  Willingness to pay for colorectal cancer screening in Guangzhou , 2018, World journal of gastroenterology.

[4]  Xiaoling Zhang,et al.  MiR-1260b inhibitor enhances the chemosensitivity of colorectal cancer cells to fluorouracil by targeting PDCD4/IGF1 , 2018, Oncology letters.

[5]  Xiao-bin Cui,et al.  miR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells , 2018, Journal of immunology research.

[6]  Yinglan Zhao,et al.  LC‑MS/MS metabolome analysis detects the changes in the lipid metabolic profiles of dMMR and pMMR cells. , 2018, Oncology reports.

[7]  W. Liu,et al.  Increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer. , 2018, European review for medical and pharmacological sciences.

[8]  Shihai Liu,et al.  MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/β-catenin signaling pathway in colorectal cancer. , 2017, Oncology letters.

[9]  Feixiang Wu,et al.  Identification of hub genes, key miRNAs and potential molecular mechanisms of colorectal cancer , 2017, Oncology reports.

[10]  J. Gu,et al.  5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. , 2017, Cancer letters.

[11]  Rakesh K. Singh,et al.  Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer. , 2017, Cancer research.

[12]  L. Ye,et al.  miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2 , 2017, Molecular therapy. Nucleic acids.

[13]  J. Bornstein,et al.  Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches. , 2017, Current medicinal chemistry.

[14]  L. Yao,et al.  miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway , 2017, World journal of gastroenterology.

[15]  N. Bhowmick,et al.  MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine , 2017, Endocrine-related cancer.

[16]  Jian Wang,et al.  MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28 , 2016, Oncotarget.

[17]  Yuan Yin,et al.  miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. , 2016, Pathology, research and practice.

[18]  Si-ying Zhou,et al.  Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis , 2016, Tumor Biology.

[19]  M. Papa,et al.  The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells , 2016, Oncotarget.

[20]  Y. Li,et al.  Unexpected requirement for a binding partner of the syntaxin family in phagocytosis by murine testicular Sertoli cells , 2015, Cell Death and Differentiation.

[21]  Jaeseung Yoon,et al.  MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis. , 2015, Experimental cell research.

[22]  Yan-bin Zhao,et al.  MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC , 2015, Scientific Reports.

[23]  S. Iwakawa,et al.  Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. , 2015, Biological & pharmaceutical bulletin.

[24]  M. Lai,et al.  MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. , 2015, Cancer letters.

[25]  Wei Li,et al.  A chromatin modifier regulates Sertoli cell response to mono-(2-ethylhexyl) phthalate (MEHP) via tissue inhibitor of metalloproteinase 2 (TIMP2) signaling. , 2014, Biochimica et biophysica acta.

[26]  Tao Yu,et al.  MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer. , 2014, Oncology reports.

[27]  Jian Jin,et al.  MiR‐489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway , 2014, FEBS letters.

[28]  P. Laurent-Puig,et al.  Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study , 2014, British Journal of Cancer.

[29]  Joseph Kim,et al.  miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal cancer metastases in the lung. , 2014, Anticancer research.

[30]  Feng Xu,et al.  Effect of miR-29b-1* and miR-29c knockdown on cell growth of the bladder cancer cell line T24 , 2013, The Journal of international medical research.

[31]  R. Bernards,et al.  TGF-β: An emerging player in drug resistance , 2013, Cell cycle.

[32]  M. Caligiuri,et al.  Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia , 2013, Clinical Cancer Research.

[33]  J. Huh,et al.  Validation of the seventh edition of the American Joint Committee on cancer tumor node‐staging system in patients with colorectal carcinoma in comparison with sixth classification , 2012, Journal of surgical oncology.

[34]  Wei Li,et al.  Sertoli Cell-specific Expression of Metastasis-associated Protein 2 (MTA2) Is Required for Transcriptional Regulation of the Follicle-stimulating Hormone Receptor (FSHR) Gene during Spermatogenesis* , 2012, The Journal of Biological Chemistry.

[35]  R. Akhurst,et al.  Complexities of TGF-β Targeted Cancer Therapy , 2012, International journal of biological sciences.

[36]  R. Tooze,et al.  BLIMP-1 and STAT3 Counterregulate MicroRNA-21 during Plasma Cell Differentiation , 2012, The Journal of Immunology.

[37]  D. Morris,et al.  RNA-binding protein IGF2BP2/IMP2 is required for laminin-β2 mRNA translation and is modulated by glucose concentration. , 2012, American journal of physiology. Renal physiology.

[38]  A. Hummon,et al.  Comparative label‐free LC‐MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5‐fluorouracil , 2012, Proteomics.

[39]  A. Duval,et al.  MiRNA Genes Constitute New Targets for Microsatellite Instability in Colorectal Cancer , 2012, PloS one.

[40]  Luigi Atzori,et al.  MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer , 2011, Clinical Cancer Research.

[41]  B. Hann,et al.  Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. , 2011, Cancer research.

[42]  Yongchang Cao,et al.  Marek's Disease Virus Type 1 MicroRNA miR-M3 Suppresses Cisplatin-Induced Apoptosis by Targeting SMAD2 of the Transforming Growth Factor Beta Signal Pathway , 2010, Journal of Virology.

[43]  Ann L Oberg,et al.  Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states , 2009, BMC Cancer.

[44]  Y. Wang,et al.  Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells , 2009, Oncogene.

[45]  K. Hunt,et al.  Effective Treatment of Advanced Colorectal Cancer by Rapamycin and 5-FU/Oxaliplatin Monitored by TIMP-1 , 2009, Journal of Gastrointestinal Surgery.

[46]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[47]  J. Yingling,et al.  Development of TGF-beta signalling inhibitors for cancer therapy. , 2004, Nature reviews. Drug discovery.

[48]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[49]  Sajeev P. Cherian,et al.  Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. , 1994, Cancer research.

[50]  R. Warrington,et al.  Susceptibility of human colon carcinoma cells to anticancer drugs is enhanced by L-histidinol. , 1994, Anticancer research.

[51]  B. Slomiany,et al.  Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice. , 1993, Cancer letters.